Ironwood Pharma (IRWD) Tops Q1 EPS by 5c, provides guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q1 EPS of $0.24, $0.05 better than the analyst estimate of $0.19. Revenue for the quarter came in at $106.51 million versus the consensus estimate of $92.11 million.

GUIDANCE:

Ironwood Pharma sees FY2026 revenue of $450-475 million, versus the consensus of $458.6 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• SpaceX (SPCX) call put ratio 1 calls to 1.1 puts as share price at $155
• Hyliion Holdings (HYLN) call put ratio 6.3 calls to 1 put with a focus on July 5, 8 and 15 calls as share price down 7.1%